• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Reporting guidelines for economic studies.

作者信息

Mason J, Drummond M

出版信息

Health Econ. 1995 Mar-Apr;4(2):85-94. doi: 10.1002/hec.4730040202.

DOI:10.1002/hec.4730040202
PMID:7613600
Abstract
摘要

相似文献

1
Reporting guidelines for economic studies.
Health Econ. 1995 Mar-Apr;4(2):85-94. doi: 10.1002/hec.4730040202.
2
A proposal: publication guidelines for healthcare improvement education reports.一项提议：医疗保健改进教育报告的出版指南。
Qual Saf Health Care. 2007 Dec;16(6):402. doi: 10.1136/qshc.2007.025189.
3
Improving the validity of economic evaluations alongside controlled trials.在对照试验的同时提高经济评估的有效性。
J Health Serv Res Policy. 1999 Jul;4(3):161-3. doi: 10.1177/135581969900400307.
4
Quality appraisal of pediatric health economic evaluations.儿科健康经济评估的质量评估
Int J Technol Assess Health Care. 2005 Spring;21(2):203-10.
5
Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force.健康经济评估报告标准（CHEERS）——解释与说明：国际卫生经济学会健康经济评估报告指南良好报告实践工作组报告。
Value Health. 2013 Mar-Apr;16(2):231-50. doi: 10.1016/j.jval.2013.02.002.
6
The EQUATOR Network and the PRISMA Statement for the reporting of systematic reviews and meta-analyses.赤道网络与系统评价和Meta分析报告的PRISMA声明。
Physiotherapy. 2009 Dec;95(4):237-40. doi: 10.1016/j.physio.2009.10.001. Epub 2009 Oct 24.
7
Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party.《英国医学杂志》经济学投稿的作者及同行评审指南。《英国医学杂志》经济评估工作小组。
BMJ. 1996 Aug 3;313(7052):275-83. doi: 10.1136/bmj.313.7052.275.
8
What Guidance are Economists Given on How to Present Economic Evaluations for Policymakers? A Systematic Review.在如何向政策制定者呈现经济评估方面，经济学家获得了哪些指导？一项系统综述。
Value Health. 2015 Sep;18(6):915-24. doi: 10.1016/j.jval.2015.06.007.
9
Guidelines for reporting health care research: advancing the clarity and transparency of scientific reporting.医疗保健研究报告指南：提高科学报告的清晰度和透明度。
Can J Anaesth. 2009 Feb;56(2):96-101. doi: 10.1007/s12630-008-9027-0.
10
Clinical trials and economic evaluations? No, there are only evaluations.
Health Econ. 1997 Jan-Feb;6(1):87-9. doi: 10.1002/(sici)1099-1050(199701)6:1<87::aid-hec249>3.0.co;2-f.

引用本文的文献

1
The quality of reporting methods and results of cost-effectiveness analyses in Spain: a methodological systematic review.西班牙成本效益分析报告方法与结果的质量：一项方法学系统评价
Syst Rev. 2016 Jan 7;5:6. doi: 10.1186/s13643-015-0181-5.
2
Viewing systematic reviews and meta-analysis in social research through different lenses.从不同视角审视社会研究中的系统评价和元分析。
Springerplus. 2014 Sep 10;3:511. doi: 10.1186/2193-1801-3-511. eCollection 2014.
3
Standardisation of costs: the Dutch Manual for Costing in economic evaluations.
成本标准化：荷兰经济评估成本核算手册
Pharmacoeconomics. 2002;20(7):443-54. doi: 10.2165/00019053-200220070-00002.
4
Criteria for evaluating evidence on public health interventions.评估公共卫生干预措施证据的标准。
J Epidemiol Community Health. 2002 Feb;56(2):119-27. doi: 10.1136/jech.56.2.119.
5
Pharmacoeconomic evaluation of new treatments: efficacy versus effectiveness studies?新疗法的药物经济学评估：疗效研究与效果研究？
Ann Rheum Dis. 1999 Nov;58 Suppl 1(Suppl 1):I82-5. doi: 10.1136/ard.58.2008.i82.
6
Challenges to the economic evaluation of new biotechnological interventions in healthcare.医疗保健领域新型生物技术干预措施经济评估面临的挑战。
Pharmacoeconomics. 1999 Aug;16(2):119-25. doi: 10.2165/00019053-199916020-00001.
7
DEC methods for appraising new drugs. Are a foundation for the nice appraisal committee.药品评价的DEC方法。是药品和保健品管理局评价委员会的基础。 （注：“nice”可能有误，推测应为“NICE”，即英国国家卫生与临床优化研究所，National Institute for Health and Care Excellence ，这里按“药品和保健品管理局”翻译，具体可根据准确信息调整）
BMJ. 1999 Oct 9;319(7215):1005; author reply 1006-7.
8
Secondary analysis of economic data: a review of cost-benefit studies of neonatal screening for phenylketonuria.经济数据的二次分析：苯丙酮尿症新生儿筛查成本效益研究综述
J Epidemiol Community Health. 1999 Mar;53(3):179-86. doi: 10.1136/jech.53.3.179.
9
Not playing with a full DEC: why development and evaluation committee methods for appraising new drugs may be inadequate.并非全用药品评价委员会：为何新药评估的研发与评估委员会方法可能并不充分。
BMJ. 1999 May 29;318(7196):1480-2. doi: 10.1136/bmj.318.7196.1480.
10
The dilemma of new drugs. Are costs rising faster than effectiveness?新药的困境。成本增长是否快于疗效？
Pharmacoeconomics. 1998 Jun;13(6):653-7. doi: 10.2165/00019053-199813060-00001.